TRAVERE THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
TRAVERE THERAPEUTICS, INC. (TVTX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $2.76 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2023-08-03
- TRAVERE THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-09-30 was $2.70M.
- TRAVERE THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-06-30 was $2.69M.
- TRAVERE THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-03-31 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month |
|---|---|---|---|
| 2023-06-30 | $2.76M 10-Q · filed 2023-08-03 | ||
| 2022-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $5.39M derived: sum of 2 quarters · filed 2023-08-03 | $5.39M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.69M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |